Gathr.ai Named a High Performer in G2's Summer 2025 Grid® Reports
G2 is the world's largest and most trusted software marketplace, used by 100 million+ people annually. The G2 Grid® Reports are based on direct feedback from real users, who rate vendors on key factors like ease of use, ability to meet requirements, core capabilities, and more. Each report is determined by G2's rigorous, data-driven Grid® Scoring Methodology, which factors in authentic product ratings.
According to the reports, Gathr.ai earned exceptional satisfaction ratings across multiple parameters, including scalability, ease of use, automation, likelihood to recommend, quality of support, and product going in the right direction.
"Every quarter, G2 ranks the best products across thousands of reports by category, company size, geography, and report type," said Sydney Sloan, CMO of G2. "These reports serve as tailored guides for software buyers researching solutions that meet their specific business needs. Congratulations to Gathr.ai for appearing in our G2 Reports this season, thanks to the positive experiences shared by their customers."
"We're thrilled to be named a High Performer in G2's Summer 2025 Grid® Reports, which represent the democratic voice of real product users," said P. C. Kiran, CEO, Gathr.ai. "Gathr.ai empowers businesses to realize their data and AI goals with unmatched speed, scale, and confidence — and we're honored that our data pipelining product has received this prestigious recognition."
About Gathr.ai
Gathr.ai powers AI with complete data context for higher quality intelligence. With day-zero, high-fidelity data discourse, users can get data-backed answers to the 'why', 'what-if', and 'how do I' questions that drive business KPIs forward. This intelligence is delivered natively on top of the organization's existing data estate — including data warehouses, databases, federated SQL engines, and operational systems.
Leading businesses across industries also rely on Gathr.ai to build high-performance data pipelines, bespoke Data+AI solutions, and action-driven analytics experiences.
Built for builders, Gathr.ai delivers speed, performance, and control. It snaps into the existing stack — integrating upstream and downstream systems with no extra plumbing. It gives developers starter-kit agility and full extension flexibility.
For more information, visit www.gathr.ai.
About G2
G2 is the world's largest and most trusted software marketplace. More than 100 million people annually — including employees at all Fortune 500 companies — use G2 to make smarter software decisions based on authentic peer reviews. Thousands of software and services companies of all sizes partner with G2 to build their reputation and grow their business — including Salesforce, HubSpot, Zoom, and Adobe. To learn more about where you go for software, visit www.g2.com and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
Cipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record Revenue
(All figures are presented in U.S. Dollars) Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025 Adjusted EBITDA 1 in Q2 2025 was $7.6 million, an increase of 148% over Q2 2024 Epuris sales volumes grew 14% in the quarter compared to Q2 2024 Natroba TM sales were $7.8 million during the quarter, a sequential increase of 16% over Q1 2025 Strong cash generation with $6.0 million cash from operations in Q2 2025 $15.0 million debt repayment and share repurchases of $2.1 million during Q2 2025 $7.0 million debt repayment subsequent to Q2 2025 MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher" or the " Company") today announced its financial and operating results for the three and six months ended June 30, 2025. First Quarter 2025 Financial Highlights (All figures in U.S. dollars, compared to Q2 2024, unless otherwise noted) Total revenue was $13.4 million in Q2 2025, an increase of 152% Canadian product portfolio revenue increased by 12% to $4.1 million in Q2 2025, compared to $3.7 million in Q2 2024 Natroba TM provided $7.8 million of incremental product revenue in Q2 2025 Licensing revenue was $1.5 million in Q2 2025, compared to $1.6 million in Q2 2024 Total gross profit from operations increased by 159% to $10.9 million in Q2 2025 Adjusted EBITDA 1 increased 148% to $7.6 million in Q2 2025 Cash balance of $11.3 million at the end of Q2 2025 Management Commentary Craig Mull, Interim CEO, commented:"Cipher has continued its growth during the second quarter of 2025, with quarterly revenue achieving a historical record for the Company, largely contributed to by our U.S. business. The U.S. business, led by Natroba™, continues to exceed our expectations from when we acquired the business almost one year ago, in July 2024. The U.S. business has contributed to a more than doubling of Cipher's total revenue and Adjusted EBITDA 1 compared to the prior year, for both the second quarter and the year-to-date. We look forward to providing further updates on the impact our strategy and activities surrounding the business have on the performance of Natroba™ for the remainder of 2025. Cipher's base business in Canada continues to experience year-over-year growth from Epuris®, with the product realizing revenue growth of 25% for the year-to-date 2025 compared to the same period in 2024, which largely offsets the decline in revenue derived from our licensing portfolio as a result of the competitive pressures faced by our commercial partners for these out-licensed products in the U.S. market." Ryan Mailling, CFO, commented: "In Q2 2025, we had another quarter of strong cash generation, with $6.0 million of cash generated from operations during the quarter. Cash generated in the second quarter, combined with previous cash accumulation, was allocated during the quarter to a $15.0 million repayment on our revolving credit facility, de-levering the business, as well as repurchases of our common shares through our normal course issuer bid ("NCIB"), which returned $2.1 million to our shareholders. After this effective use of available capital, at the end of the second quarter $11.3 million of cash remained on our balance sheet. Accordingly, subsequent to the end of the quarter we further allocated $7.0 million to an additional repayment on our revolving credit facility, resulting in $47.0 million of financing remaining available through the facility, plus a $25.0 million accordion option, which in total is $72.0 million of total potential financing available. We continue to be in an excellent position to execute on growth opportunities." Corporate Highlights On April 29, 2025, Cipher announced its product Natroba TM received preferred step-through status on Medicaid in the state of Illinois, whereby its main product competitor Permethrin 5% was downgraded to non-preferred on the state's preferred drug listing. This move by Illinois Medicaid will require all prescriptions for Permethrin 5% to first 'step-though' Natroba TM representing the treatment of choice in the state. On May 1, 2025, Cipher announced that the Toronto Stock Exchange (the "TSX") had approved the Company's Notice of Intention to Make a Normal Course Issuer Bid under which the Company may purchase for cancellation, from time to time up to May 4, 2026, up to an aggregate of 1,485,260 of its issued and outstanding common shares, being 10% of its public float of 14,852,604 common shares as of April 22, 2025. In accordance with TSX rules, any daily repurchases on the TSX under the NCIB are limited to a maximum of 10,427 common shares, which represents 25% of the average daily trading volume on the TSX of 41,708 for the six months ended March 31, 2025. To facilitate larger repurchases, the Company is entitled to make one weekly block purchase on the TSX that may exceed the daily repurchase restrictions. On May 8, 2025, the Company repaid $15.0 million of the outstanding balance on its revolving credit facility. On August 6, 2025, the Company repaid $7.0 million of the remaining outstanding balance on its revolving credit facility. As a result of the repayment, the outstanding balance on the Company's revolving credit facility has been reduced to $18.0 million. Due to the revolving nature of the credit facility, an additional $47.0 million remains available to the Company to draw upon, should financing be required. Q2 2025 Financial Review (All figures in U.S. dollars, compared to Q2 2024, unless otherwise noted) Total revenue was $13.4 million in Q2 2025, compared to $5.3 million in Q2 2024, an increase of 152% Product revenue from the Canadian product portfolio was $4.1 million in Q2 2025, an increase of 12% from $3.7 million in Q2 2024 Product revenue from Natroba TM in the U.S. was $7.8 million, up sequentially from $6.7 million in Q1 2025 Licensing revenue decreased 9% to $1.5 million in Q2 2025 compared to $1.6 million in Q2 2024, impacted by lower net sales realized by Cipher's partners on which the Company earns a royalty and contractual royalty rate reductions, partially offset by higher product shipments to licensing partners Total gross profit was $10.9 million in Q2 2025, compared to $4.2 million in Q2 2024, an increase of 159% Gross margin as a percentage of product revenue increased by 9% to 79% in Q2 2025 from 70% in Q2 2024, driven by the addition of Natroba™, which was acquired on July 29, 2024 Total gross margin increased by 2% to 81% in Q2 2025 from 79% in Q2 2024 due to the addition of Natroba™, partially offset by reduced licensing revenue Net income and earnings per common share were $5.9 million and $0.23, respectively, in Q2 2025, compared to $3.0 million and $0.12, respectively, in Q2 2024, with the increase primarily attributable to the additional operating income generated from Natroba™ in Q2 2025 EBITDA 1 in Q2 2025 was $8.6 million, compared to $2.2 million in Q2 2024, an increase of 290% Adjusted EBITDA 1 in Q2 2025 was $7.6 million, compared to $3.1 million in Q2 2024, an increase of $4.5 million or 148% Adjusted EBITDA 1 per share in Q2 2025 was $0.29 compared to $0.13 in Q2 2024, an increase of $0.16 per share or 123% Under the Company's NCIB, 230,278 common shares were repurchased and cancelled at an average share price of CDN$12.74 Business Strategy & Outlook Cipher expects to continue to execute on its business strategy, remains focused on profitability and delivering shareholder value. Key areas of focus include: Driving market share growth of Natroba™ in the anti-parasitic market in the U.S. where market leader "Permethrin" is no longer an effective treatment but still holds 75% 2 market share. Obtaining Health Canada regulatory approval for Natroba™ and commercializing the product directly in the Canadian market by leveraging Cipher's existing infrastructure in Canada. Out-licensing Natroba™ globally where there is high unmet need, such as warm climate regions. Acquiring complementary dermatology products to add to our North American platform to enhance the profitability, size and scale of the business. Financial Statements and MD&A Cipher's financial statements for the three and six months ended June 30, 2025, and Management's Discussion and Analysis (the "MD&A") for the three and six months ended June 30, 2025, are available on the Company's website at in the "Investors" section under "Financial Reports" and on SEDAR+ at Notice of Conference Call Cipher will hold a conference call on August 8, 2025 at 8:30 a.m. (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial (416) 945-7677 or (888) 699-1199 A live audio webcast will be available at An archived replay of the webcast will be available until August 15, 2025 and can be accessed by dialing (289) 819-1450 or (888) 660-6345 and entering conference replay code 36094# About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit Forward-Looking Statements and Non-IFRS Measures This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, expectations for future growth, objectives and goals and strategies to achieve those objectives and goals, the potential purchases to be made under the NCIB, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire; the extent and impact of health pandemic outbreaks on our business; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; the product approval process by regulators which can be highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the Company's performance depends, in part, on the performance of its distributors and suppliers; the pharmaceutical industry is highly competitive with new competing product entrants; requirements for additional capital to fund future operations; products may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; the ability to receive regulatory approvals for products in development or future products; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; the ability to convince public payors and hospitals to include our products on the approved formulary lists; ability to receive timely payment from certain customers; application of various laws pertaining to health care fraud and abuse; the Company's reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the healthcare industry generally; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; success in applying tax loss carry forwards; inability to meet covenants under our long-term debt arrangement; compliance with privacy and security regulation; our policies regarding product returns, allowances and chargebacks may reduce revenues; additional regulatory burden and controls over financial reporting; application of regulations that could restrict our activities and abilities to generate revenues as planned; reliance on third parties to perform distribution, logistics, invoicing, regulatory and sales services; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States; increases in tariffs, trade restrictions or taxes on our products; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the fact that we have a significant shareholder; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up. We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the "Risk Factors" section of our MD&A for the year ended December 31, 2024 and the Company's Annual Information Form, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language. 1) EBITDA and adjusted EBITDA are non-IFRS financial measures. These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are unlikely to be comparable to similar measures presented by other companies. Management uses non-IFRS measures such as Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA to provide investors with supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. The Company defines Adjusted EBITDA as earnings before interest expense, income taxes, depreciation of property and equipment, amortization of intangible assets, non-cash share-based compensation, changes in fair value of derivative financial instruments, costs and provisions for legal matters, loss on disposal of assets and loss on extinguishment of lease, impairment of intangible assets, acquisition costs, restructuring costs, fair value adjustments to acquired inventory and unrealized foreign exchange gains and losses. 2) IQVIA market data as at June 30, 2025. The following is a summary of how EBITDA and Adjusted EBITDA are calculated: (IN THOUSANDS OF U.S. DOLLARS, Three months ended June 30, 2025 Three months ended June 30, 2024 Six months ended June 30, 2025 Six months ended June 30, 2024 except for per share amounts) $ $ $ $ Net income and comprehensive income 5,893 2,995 8,517 7,918 Add back: Depreciation and amortization 1,807 292 3,629 581 Interest expense (income) 345 (611) 815 (1,166) Income tax expense (recovery) 512 (480) (225) (2,435) EBITDA 8,557 2,196 12,736 4,898 Unrealized foreign exchange (gain) loss (1,759) 401 (1,770) 1,043 Acquisition, restructuring and other costs — 284 128 284 Fair value adjustments to acquired inventory 131 — 777 — Costs and provisions for legal matter 221 — 1,221 — Share-based compensation 436 183 680 407 Adjusted EBITDA 7,586 3,064 13,772 6,632 Adjusted EBITDA per share – basic 0.29 0.13 0.54 0.28 Adjusted EBITDA per share – dilutive 0.29 0.12 0.52 0.27 Consolidated statements of income and comprehensive income Three months ended June 30, Six months ended June 30, (IN THOUSANDS OF U.S. DOLLARS, 2025 2024 2025 2024 except for per share amounts) $ $ $ $ Revenue Licensing revenue 1,478 1,618 2,213 4,218 Product revenue 11,903 3,686 23,187 6,953 Net revenue 13,381 5,304 25,400 11,171 Operating expenses Cost of products sold 2,498 1,106 5,377 2,161 Research and development — — 21 — Depreciation and amortization 1,807 292 3,629 581 Selling, general and administrative 4,085 1,601 9,036 3,069 Total operating expenses 8,390 2,999 18,063 5,811 Other (income) expenses Interest expense (income) 345 (611) 815 (1,166) Unrealized foreign exchange (gain) loss (1,759) 401 (1,770) 1,043 Total other (income) expenses (1,414) (210) (955) (123) Income before income taxes 6,405 2,515 8,292 5,483 Current income tax expense — — — — Deferred income tax expense (recovery) 512 (480) (225) (2,435) Total income tax expense (recovery) 512 (480) (225) (2,435) Net income and comprehensive income for the period 5,893 2,995 8,517 7,918 Income per share Basic 0.23 0.12 0.33 0.33 Diluted 0.22 0.12 0.32 0.32 Consolidated statements of financial position As at June 30, As at December 31, 2025 2024 (IN THOUSANDS OF U.S. DOLLARS) $ $ Assets Current assets Cash and cash equivalents 11,339 17,837 Accounts receivable 11,868 13,860 Inventory 5,576 5,792 Prepaid expenses and other assets 1,766 995 Total current assets 30,549 38,484 Property and equipment 522 680 Intangible assets 75,287 78,754 Deferred financing costs 311 386 Goodwill 17,447 17,447 Deferred tax assets 28,278 26,761 Total assets 152,394 162,512 Liabilities and shareholders' equity Current liabilities Accounts payable and accrued liabilities 4,846 5,873 Income taxes payable 9 54 Interest payable 82 358 Contract liabilities 12,564 13,306 Current portion of lease obligation 262 283 Total current liabilities 17,763 19,874 Lease obligation 193 295 Long-term debt 25,000 40,000 Total liabilities 42,956 60,169 Shareholders' equity Share capital 27,556 27,680 Contributed surplus 7,149 6,525 Accumulated other comprehensive loss (9,514) (9,514) Retained earnings 84,247 77,652 Total shareholders' equity 109,438 102,343 Total liabilities and shareholders' equity 152,394 162,512 SOURCE Cipher Pharmaceuticals Inc.
Cision Canada
10 hours ago
- Cision Canada
FP Canada™ Announces June CFP® Exam and QAFP® Exam Results
Of the first-time writers who completed the CFP exam, 81% passed. Seventy-five per cent of first-time QAFP exam writers passed. TORONTO, Aug. 7, 2025 /CNW/ - FP Canada has announced the results for the June sittings of the Certified Financial Planner ® exam and the Qualified Associate Financial Planner ™ exam. There were 385 candidates who wrote the CFP exam (and 81% of the first-time writers passed), while 50 candidates wrote the QAFP exam (and the first-time writer pass rate was 75%). FP Canada administered a survey to all candidates who wrote the exams. According to that survey, 82% of CFP exam writers decided to pursue certification so they could enhance their skills and better serve their clients. The same was true for 76% of candidates pursing QAFP certification. Forty-nine per cent of CFP candidates and 48% of QAFP candidates indicated that provincial legislation requiring them to obtain an approved certification to use the "financial planner" title was a major motivator. Likewise, 30% of CFP exam writers and 24% of those who wrote the QAFP exam stated that their pursuit of certification was driven largely by an employer requirement. "We at FP Canada would like to sincerely congratulate everyone who successfully wrote the CFP exam or QAFP exam in June," says Tashia Batstone, President and CEO of FP Canada. "Completing this critical step toward certification is a tremendous accomplishment—one that brings you closer to being fully qualified to help Canadians find their paths to financial well-being." To obtain CFP certification, candidates must complete a comprehensive education program that includes professional education, pass a national exam, have (at minimum) a bachelor's degree or 10 years of qualifying work experience (or have held QAFP certification for at least five years), and demonstrate three years of qualifying work experience. QAFP certification candidates must complete a comprehensive education program, pass a national exam, have a post-secondary diploma or five years of qualifying work experience, and demonstrate one year of qualifying work experience. To maintain certification, CFP professionals must ensure their knowledge and skills remain current by completing 25 hours of continuing education each year, including two hours in the professional responsibility category. QAFP professionals must complete 12 hours of continuing education each year, including one hour in the professional responsibility category. CFP professionals and QAFP professionals must also adhere to high professional standards established by the FP Canada Standards Council ™. CFP certification and QAFP certification have been approved by the Financial Services Regulatory Authority of Ontario (FSRA) as valid credentials for individuals using the "financial planner" title in Ontario. Established in 1995, FP Canada is a national not-for-profit education, certification and professional oversight organization working in the public interest. FP Canada is dedicated to championing better financial wellness for all Canadians by leading the advancement of professional financial planning in Canada.
Cision Canada
13 hours ago
- Cision Canada
Diamonds Direct® Entered into Canadian Licensing Agreement
TORONTO, Aug. 7, 2025 /CNW/ - As previously announced by Birks Group Inc. ("Birks") in connection with its acquisition of the European Boutique business, Canadian brand Diamonds Direct® has entered into a licensing agreement with Birks for the operation of the brand in the Greater Toronto Area through brick-and-mortar showrooms and nationally through the brand's e-commerce platform Jordan Sutkiewicz and Michelle Ceresney (co-CEOs of Diamonds Direct®) commented: "The licensing agreement with Birks is an exciting milestone for Diamonds Direct®. We have laid the foundation for the successful operation of the brand with an experienced Canadian retail partner. As part of our global growth initiative, we are evaluating additional licensing opportunities for Diamonds Direct® in the United Kingdom, Mexico, Asia and Europe, as well as for Watches Direct® in the United States." The licensing agreement follows the opening of storefronts for Diamonds Direct® at Square One Shopping Centre in Mississauga and CF Sherway Gardens in Etobicoke, as well as a new Watches Direct® concept at Yorkdale Shopping Centre in Toronto. Diamonds Direct® has also recently launched its proprietary engagement ring line that will showcase hundreds of new ring styles in-store and online at and
